321 related articles for article (PubMed ID: 9647491)
1. Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation.
Barsotti G; Cupisti A; Morelli E; Meola M; Cozza V; Barsotti M; Giovannetti S
Nephron; 1998; 79(2):137-41. PubMed ID: 9647491
[TBL] [Abstract][Full Text] [Related]
2. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
[TBL] [Abstract][Full Text] [Related]
3. Long-term control of hyperparathyroidism in advanced renal failure by low-phosphorus low-protein diet supplemented with calcium (without changes in plasma calcitriol).
Combe C; Morel D; de Précigout V; Blanchetier V; Bouchet JL; Potaux L; Fournier A; Aparicio M
Nephron; 1995; 70(3):287-95. PubMed ID: 7477615
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure.
Martinez I; Saracho R; Montenegro J; Llach F
Am J Kidney Dis; 1997 Apr; 29(4):496-502. PubMed ID: 9100037
[TBL] [Abstract][Full Text] [Related]
6. Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure.
Tsukamoto Y; Moriya R; Nagaba Y; Morishita T; Izumida I; Okubo M
Am J Kidney Dis; 1995 Jun; 25(6):879-86. PubMed ID: 7771484
[TBL] [Abstract][Full Text] [Related]
7. Effect of protein and phosphate restricted and calcium and alphacalcidol supplemented diet on renal and parathyroid functions and protein status in chronic renal failure patients.
Nand N; Aggarwal HK; Anupam ; Sharma M
J Assoc Physicians India; 1999 Sep; 47(9):869-73. PubMed ID: 10778654
[TBL] [Abstract][Full Text] [Related]
8. Reversal of hyperparathyroidism in severe uremics following very low-protein and low-phosphorus diet.
Barsotti G; Morelli E; Guiducci A; Ciardella F; Giannoni A; Lupetti S; Giovannetti S
Nephron; 1982; 30(4):310-3. PubMed ID: 7110461
[No Abstract] [Full Text] [Related]
9. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus.
Bover J; Jara A; Trinidad P; Rodriguez M; Felsenfeld AJ
Bone; 1999 Sep; 25(3):279-85. PubMed ID: 10495131
[TBL] [Abstract][Full Text] [Related]
11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
12. Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements.
Teruel JL; Tenorio MT; Rodríguez JR; Marc n R; Orofino L; Rivera M; Ortuño J
Am J Nephrol; 1999; 19(3):428-32. PubMed ID: 10393383
[TBL] [Abstract][Full Text] [Related]
13. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
14. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
15. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
[TBL] [Abstract][Full Text] [Related]
16. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.
Chertow GM; Dillon M; Burke SK; Steg M; Bleyer AJ; Garrett BN; Domoto DT; Wilkes BM; Wombolt DG; Slatopolsky E
Clin Nephrol; 1999 Jan; 51(1):18-26. PubMed ID: 9988142
[TBL] [Abstract][Full Text] [Related]
18. Phosphorus and protein restriction and parathyroid function in chronic renal failure.
Combe C; Aparicio M
Kidney Int; 1994 Nov; 46(5):1381-6. PubMed ID: 7853797
[TBL] [Abstract][Full Text] [Related]
19. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
20. The interaction of PTH and dietary phosphorus and calcium on serum calcitriol levels in the rat with experimental renal failure.
Martin-Malo A; Rodriguez M; Martinez ME; Torres A; Felsenfeld AJ
Nephrol Dial Transplant; 1996 Aug; 11(8):1553-8. PubMed ID: 8856210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
